M-S-T Compound Spacer for Gas-Filled Microvesicle Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gas-filled microvesicle formulations lack effective spacer moieties to bind targeting ligands or therapeutic agents, particularly for hydrophobic components, limiting their diagnostic and therapeutic efficacy in ultrasound imaging and drug delivery.
Innovation Solution
A compound of the formula M-S-T is introduced, where M represents an envelope-forming component, S is a spacer with at least two sulfone groups for bridging the envelope and a targeting or therapeutic agent T, allowing for effective association even with hydrophobic agents, enhancing binding activity and echogenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional polymeric spacers are used to bind targeting ligands or therapeutic agents to microvesicles, then the binding capability is achieved, but the spacer length must be relatively long which increases molecular complexity and reduces binding efficiency for hydrophobic components
Solution Approach 1:
The patent changes the chemical parameters of the spacer by introducing sulfone groups (—SO2—) which have high hydrophilicity. This parameter change allows the spacer to effectively bind both hydrophilic and hydrophobic components, achieving reliable binding activity without requiring excessive length, thus reducing molecular complexity while maintaining or enhancing binding efficiency.
Solution Approach 2:
The spacer component S is designed as a composite structure containing at least two sulfone groups combined with hydrocarbon chains (—(CH2)m—). This composite approach creates a spacer that combines the hydrophilic properties of sulfone groups with the structural flexibility of hydrocarbon chains, enabling effective binding to both polar and non-polar components while maintaining optimal length.
2Reliability
If longer polymeric spacers are used to accommodate hydrophobic therapeutic agents, then binding capability is maintained, but the hydrophilicity of the microvesicle surface is reduced which affects circulation stability and diagnostic imaging quality
Solution Approach 1:
The patent modifies the chemical composition parameters of the spacer by incorporating at least two sulfone groups. These groups contribute high hydrophilicity to the spacer structure, ensuring that even when binding hydrophobic therapeutic agents, the overall hydrophilicity of the microvesicle surface is maintained, thus preserving circulation stability and diagnostic imaging quality while maintaining binding capability.
3Adaptability or versatility
If multiple different spacer moieties are developed for different targeting ligands and therapeutic agents, then versatility in binding different components is achieved, but the complexity of formulation development and manufacturing increases
Solution Approach 1:
The patent creates a universal spacer component S containing sulfone groups that can bind both hydrophilic and hydrophobic components. This multi-functional spacer design eliminates the need to develop separate spacer moieties for different types of targeting ligands or therapeutic agents, thereby maintaining binding versatility while significantly simplifying formulation development and manufacturing processes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The M-S-T compound enables superior binding activity and echogenicity of gas-filled microvesicles, facilitating enhanced diagnostic imaging and therapeutic delivery, particularly in ultrasound applications.
Implementation Method 1
the high hydrophilicity of the at least two sulfone groups included into the spacer component 'S' allows to use spacers of relatively short length
Data Source
AI summary
New targeting or therapeutic compounds which can be incorporated into a composition of gas-filled microvesicles. The invention further relates to gas-filled microvesicles for diagnostic and/or therapeutic use comprising said compounds and to their method of use. The new compounds are compounds of formula M-S-T, wherein: M represents a component capable of associating with an envelope of a gas-filled microvesicle; T represents a component comprising a targeting ligand or a therapeutic agent; and S represents a component comprising at least two bissulfone groups.